BSX · 10-Q · 2026Q2 · Full report

Restructuring Charges

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 64 · Surprise 42 · In source text

Boston Scientific’s 2023 Restructuring Plan, expanded by up to $250 million in July 2025, has an estimated total pre-tax cost of approximately $700 million to $800 million. The program covers manufacturing-line transfers, termination benefits, consulting and contract-cancellation costs, facility-related impairments, accelerated depreciation and fixed-asset write-offs. Activities under the expanded plan were substantially complete at the end of 2025. On July 21, 2026, the Board approved and the company committed to a new global restructuring program, with further details assigned to Note M.

Key facts

• On July 21, 2026, the Board approved and the company committed to a new global restructuring program. source
• The 2023 Restructuring Plan, including the July 29, 2025 expansion up to $250 million, is estimated to result in total pre-tax charges of approximately $700 million to $800 million and activities were substantially complete at the end of 2025. source

Impact estimates